An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients

Guangzhou Medical University

Status: Not yet enrolling

Conditions: LUNG CANCER

Treatments: Biological: 23-valent pneumococcal vaccine

Study type: Observational

Funder types: Other

Identifiers

NCT07142057

23V-PNEUMO-LC

Details and patient eligibility

About

To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female patients >=18 years of age;
2. Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;
3. Never received pneumococcal vaccine

Exclusion criteria

Patients having other factors that preventing researchers from enrollment them.

Trial design

500 participants in 2 patient groups

Vaccination group

Description:

Lung cancer patients receive 23-valent pneumonia vaccine

Treatment:

Biological: 23-valent pneumococcal vaccine

Unvaccinated group

Description:

Lung cancer patients have not received the 23-valent pneumococcal vaccine